We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Table S1 Sample Clauses

Table S1. UV-Vis spectra of 1-8 in methanol and acetonitrile (λ in nm, ε in M-1cm-1). S λmax, MeOH εmax# ε254# λmax, ACN εmax# ε254# 1 H 225.9 2.56*104 4.21*103 229.1 2.02*104 9.10*103 2 CH3 244.9 2.61*104 2.12*104 250.0 1.74*104 1.68*104 3 OCH2CH3 247.0 1.82*104 1.56*104 251.1 1.55*104 1.52*104 4 CF3 226.0 1.75*104 1.76*103 226.0 2.14*104 8.52*103 5 C(O)OCH3 236.0 1.83*104 6.68*103 238.0 2.60*104 6.68*103 6 CN 236.9 3.17*104 9.61*103 239.0 2.93*104 1.54*104 7 C(O)CH3 244.0 3.36*104 2.35*104 244.0 0.27*104 2.09*104 8 N(Me)2 304.0 2.03*104 1.37*104 311.1 1.70*103 1.95*104 # εmax is absorption coefficient at maximum absorption, ε 254 is absorption coefficient at λ = 254 nm.
AutoNDA by SimpleDocs
Table S1. Residues showing significant differences in 1H and 15N chemical shifts ($Dav>0.3) between V44M IGF-I and IGF-I plus F1 peptide (8), where $Dav=($DNH2 + 0.17$D 2)1/2 (66). Chemical shifts for these residues in long-[Arg3] IGF-I (10) and long-[Leu60] IGF-I (11) are also included. The residues implicated in F1 peptide binding actions (8) are shown in black and others shaded in gray. Cys 6 8.25 120.2 8.47 118.0 8.38 119.7 8.33 118.3 Gly7* ------- ------- 8.86 109.7 7.74 110.0 7.63 108.3# Ala8* 8.49 126.5 8.77 128.5 8.98 130.3 8.83 128.2 Glu9 7.61 114.5 7.80 115.5 8.00 118.1 7.94 115.1# Leu10* ------- ------- 6.74 119.9 6.88 121.7 6.87 120.3 Val11 7.59 115.7 7.18 118.1 7.29 119.3 7.38 117.9 Phe16 7.71 119.0 8.29 121.2 7.84 120.6 7.38 117.9# Phe25 7.93 117.3 8.53 116.9 8.48 119.6 7.86 120.3# Ile43 7.91 120.4 7.58 121.5 7.89 122.4 7.74 121.4 Phe49 7.45 115.9 7.70 116.1 7.72 117.3 7.89 113.7# Arg50 7.93 116.5 7.42 117.1 7.53 119.9 7.95 119.4 Ser51 7.90 112.9 7.75 110.7 7.83 113.3 7.81 112.9 Leu54 7.73 122.6 8.67 127.0 7.59 123.6 7.57 122.5# Arg55 7.80 118.0 8.22 117.5 7.86 119.9 7.92 119.4 Glu58* ------- ------- 7.40 112.5 8.09 114.8 8.15 113.7 Tyr60 7.76 115.8 7.81 117.5 7.98 117.0 7.76 117.9 Cys61* ------- ------- 7.09 7.26 116.9 7.22 115.3 * Gly7, Leu10, Glu58 and Cys61 are not found in any spectra of 15˚C, 20˚C and 37˚C in V44M IGF-I. + Ala8 has a very weak peak in 2D HSQC. # Chemical shifts show significant differences among the three published IGF-I data sets. Table S2. XXX intensities observed in Val44Met IGF-I compared with inter-proton distances for the mutated residue 44 in A) long-[Arg3] IGF-I (12) and B) IGF-I plus F1 peptide (8). Relative intensities (RI), calculated using the integrated intensity divided by the average noise in the 3D NOESY-HSQC spectrum, are designated S (strong, RI>3.5), M (medium, 3.5>RI>2.0) and W (weak, RI<2.0). HN-HN and HN-HA NOEs and corresponding distances are shaded in grey. Note that the relative strengths of the sequential NOEs to Met44 HN correspond more closely with the distances in the long-[Arg3] IGF-I structure. Several backbone-to-backbone NOEs expected from the long-[Arg3] IGF-I structure are not seen in spectra of Val44Met IGF-I as follows: HN of Asn26, Gly42, Glu46, Cys47, Cys48 to Met44 HN; HN of Leu10, Val11, Glu46, Cys47, Cys48 to Met44 HA. NOEs expected from the IGF-I+F1 structure but not seen in spectra of Val44Met IGF-I are: HN of Gly42, Glu46, Cys47, Cys48 to Met44 HN; HN of Glu46, Cys47, Cys48, Phe49 to Met...
Table S1. The Bowdle scales8
Table S1. The Primers Used for qRT-PCR‌
Table S1. Analytical (AEF) and surface (SEF) enhancement factors estimated at an R6G analyte concentration of 10-6 M and an excitation wavelength of 632.8 nm.
Table S1. Partial correlation coefficients between the five climatic covariates. None of the correla- tions was significant.
Table S1. CLL VH gene families and HCDR3 sequences Donor IGHV1-69*01 IGHD3-3*01 IGHJ4*02 ARVTVKYYDFWGYYFDY 1153 IGHV1-69*01 IGHD3-3*01 IGHJ4*02 DDSYYDFWSGWYY 1012 IGHV1-69*01 IGHD3-3*01 IGHJ6*03 ARVEIFGVVGLSYYYYYMDV 1640 IGHV1-69*01 IGHD3-3*01 IGHJ6*03 ARGAIFGVVIIPVTPFYMDV 859 IGHV3-09*01 IGHD3-3*01 IGHJ4*02 AKDASSNYDFWSGYYDY 1371 IGHV4-b*02 IGHD3-3*01 IGHJ4*02 ARVMEKYYDFWSGYYYFD 1324 IGHV1-69*01 IGHD3-10*01 IGHJ6*03 AREASYGSGSYYQQYYYYYYMDV 1333 IGHV1-69*01 IGHD3-10*01 IGHJ6*02 AVGVLWFGELLFSYYYYYGMD 352 IGHV1-69*05 IGHD3-3*01 IGHJ6*02 AGRLIFGVVITAGGDYGMDV 1301 IGHV4-31*03 IGHD3-3*01 IGHJ3*02 ARAPIGSTIFGVVIIRFAFDI 276 IGHV1-2*02 IGHD2-21*02 IGHJ4*02 ARTQIGDCGGDCYPFDY 336 IGHV1-3*01 IGHD6-19*01 IGHJ4*02 AREQWLVLSYFDY 606 IGHV1-2*04 IGHD3-10*01 IGHJ4*02 ARDLRYSYGSGSTPFLDS 758 IGHV1-18*01 IGHD3-16*01 IGHJ4*02 ARKSWVGAYYFDY 854 IGHV1-3*01 IGHD2-2*01 IGHJ4*02 VSHYCTSSTCDQMY 1222 IGHV1-2*02 IGHD6-19*01 IGHJ4*02 AREQWLASPNLDY 1271 IGHV4-34*02 IGHD6-6*01 IGHJ4*02 ARGRWSPKFVL 1299 IGHV3-23*01/IGHV3-23*02 IGHD2-2*01 IGHJ4*03 AKGLVIGLPDV 1330 IGHV3-7*03 IGHD2-8*01 IGHJ4*02 ARSSRDGTNDYDGEYRYFDY 1240 IGHV3-33*01/IGHV3-33*06 IGHD3-9*01 IGHJ2*01 ATRPQLNYDILTGYYIGGGYFDL 1294 IGHV3-21*01 IGHD7-27*01 IGHJ6*03 ARDPYRGLYGMFYFYYMDV 1317 IGHV4-59*01 IGHD2-21*02 IGHJ3*02 ARNPYCGGDCYSDAFDI 1319 IGHV4-31*03 IGHD2-2*02 IGHJ6*02 ARDLYGWTYCSSTSCYRYYGMDV 1326 IGHV3-53*04 IGHD5-12*01 IGHJ6*02 ARDRVDIVATTTYYYYYYGMDV 1344 IGHV1-69*02 IGHD2-21*02 IGHJ5*02 ARSTNLDYFFAAVTGNWFDP 1358 IGHV4-34*02 IGHD2-8*01 IGHJ6*02 TRAMDYYYGMDV 1397 IGHV1-69*06 IGHD3-22*01 IGHJ6*02 ATPPRGTYDSSGYYYGGLDNYYGMDV Table S1: CLL VH gene families and HCDR3 sequences. The IGHV, IGHD, and IGHJ genes and the HCDR3 amino acid sequences expressed in the leukemic cells of 26 CLL patients tested for VLR39 reactivity are shown. Shared VH gene family usage between CLL donor and other CLL patients are highlighted in yellow (IGHV), blue (IGHD), and green (IGHJ). CLL VH gene family determination and all sequences were provided by R. Catera and X. Xxxxxxxxx.
AutoNDA by SimpleDocs
Table S1. Researches concerning racial disparity in type II endometrial Author (Citation) Data Source Time period Racial of data Factors examined (year of publication) included groups
Table S1Statistical analysis of the differences between mean GH space values as

Related to Table S1

  • Definitions and Basic Provisions The following definitions and basic provisions shall be used in conjunction with and limited by the reference thereto in the provisions of this lease:

  • Purpose; Incorporation by Reference of Auction Procedures and Settlement Procedures (a) On each Auction Date, the provisions of the Auction Procedures will be followed by the Auction Agent for the purpose of determining the Applicable Rate for the of APS, for the next Dividend Period therefor. Each periodic operation of such procedures is hereinafter referred to as an "Auction." (b) All of the provisions contained in the Auction Procedures and the Settlement Procedures are incorporated herein by reference in their entirety and shall be deemed to be a part of this Agreement to the same extent as if such provisions were set forth fully herein. (c) BD agrees to act as, and assumes the obligations of and limitations and restrictions placed upon, a Broker-Dealer under this Agreement. BD understands that other Persons meeting the requirements specified in the definition of "Broker-Dealer" contained in Paragraph 10 of Article VII of the Amended By-laws may execute a Broker-Dealer Agreement and participate as Broker-Dealers in Auctions. (d) BD and other Broker-Dealers may participate in Auctions for their own accounts. However, the Trust, by notice to BD and all other Broker Dealers, may prohibit all Broker-Dealers from submitting Bids in Auctions for their own accounts, provided that Broker-Dealers may continue to submit Hold Orders and Sell Orders.

  • Definitions Etc For purposes of this Section 5 and Section 7: The issuance of any warrants, options or other subscription or purchase rights with respect to shares of Common Stock and the issuance of any securities convertible into or exchangeable for shares of Common Stock (or the issuance of any warrants, options or any rights with respect to such convertible or exchangeable securities) shall be deemed an issuance at such time of such Common Stock if the Net Consideration Per Share which may be received by the Company for such Common Stock (as hereinafter determined) shall be less than the Purchase Price at the time of such issuance and, except as hereinafter provided, an adjustment in the Purchase Price and the number of shares of Common Stock issuable upon exercise of this Warrant shall be made upon each such issuance in the manner provided in Section 5. 1. Any obligation, agreement or undertaking to issue warrants, options, or other subscription or purchase rights at any time in the future shall be deemed to be an issuance at the time such obligation, agreement or undertaking is made or arises. No adjustment of the Purchase Price and the number of shares of Common Stock issuable upon exercise of this Warrant shall be made under Section 5.1 upon the issuance of any shares of Common Stock which are issued pursuant to the exercise of any warrants, options or other subscription or purchase rights or pursuant to the exercise of any conversion or exchange rights in any convertible securities if any adjustment shall previously have been made upon the issuance of any such warrants, options or other rights or upon the issuance of any convertible securities (or upon the issuance of any warrants, options or any rights therefor) as above provided. Any adjustment of the Purchase Price and the number of shares of Common Stock issuable upon exercise of this Warrant with respect to this Section 5.2 which relates to warrants, options or other subscription or purchase rights with respect to shares of Common Stock shall be disregarded if, as, and to the extent that such warrants, options or other subscription or purchase rights expire or are canceled without being exercised, so that the Purchase Price effective immediately upon such cancellation or expiration shall be equal to the Purchase Price that otherwise would have been in effect at the time of the issuance of the expired or canceled warrants, options or other subscriptions or purchase rights, with such additional adjustments as would have been made to that Purchase Price had the expired or cancelled warrants, options or other subscriptions or purchase rights not been issued. For purposes of this Section 5.2, the "Net Consideration Per Share" which may be received by the Company shall be determined as follows:

  • Basic Lease Provisions and Definitions In addition to other terms elsewhere defined in this Lease, the following terms whenever used in this Lease should have only the meanings set forth in this Preamble, unless such meanings are expressly modified, limited or expanded elsewhere herein.

  • GUARANTEED DISPLAY REFERRAL FEE WAIVERS XXXX.xxx offers a paid featured agent program referred to as “Guaranteed Display.” This paid product provides the following Referral Fee benefits to the Recipient Broker/Agent: • If a closing results from a lead originated during the time, and in the zip code, that the Recipient Broker/Agent was an active Guaranteed Display sponsor, the referral fee will be discounted from the standard 35% to 30%. • If a closing results from a lead originated during the time, and in the zip code, that the Recipient Broker/Agent was an active Guaranteed Display sponsor, and if XXXX.xxx was not responsible for brokering an appointment between the Referred Client and the Recipient Broker/ Agent, the referral fee will be waived entirely to 0%. To qualify for this Referral Fee waiver, Recipient Broker/Agent must update the Referral Status in the XXXX.xxx Agent Portal (xxxxx://xxxxxx.xxxx.xxx) to reflect the property has been listed prior to XXXX.xxx indicating that an appointment has been set.

  • Limit on Number of Partners Unless otherwise permitted by the General Partner in its sole and absolute discretion, no Person shall be admitted to the Partnership as an Additional Limited Partner if the effect of such admission would be to cause the Partnership to have a number of Partners that would cause the Partnership to become a reporting company under the Exchange Act.

  • Sector Sub-Sector Industry Classification Level of Government Type of Obligation Description of Measure Source of Measure All sectors : : - : Central : National Treatment Senior Management and Board of Directors : National Treatment and the Senior Management and Board of Directors obligations shall not apply to any measure relating to small and medium sized domestic market enterprise2. Foreign equity is restricted to a maximum of 40% for domestic market enterprises with paid-in equity capital of less than the equivalent of USD 200,000 Note: Members of the Board of Directors or governing body of corporation or associations shall be allowed in proportion to their allowable participation or share in the capital of such enterprises. : -1987 Constitution of the Republic of the Philippines. - Foreign Investments Act of 1991 (R.A. No. 7042, as amended by R.A. No. 8179). -Presidential and Administrative Issuances. ∞ 2 The concept of a small and medium sized domestic market enterprise is an enterprise with paid in equity capital of less than the equivalent of USD 200,000.00.

  • Geographic Area and Sector Specific Allowances, Conditions and Exceptions The following allowances and conditions shall apply where relevant. Where the Employer does work which falls under the following headings, the Employer agrees to pay and observe the relevant respective conditions and/or exceptions set out below in each case.

  • State Specific Provisions N/A. ATTACHED EXHIBIT. The Exhibit noted below, if marked with an "X" in the space provided, is attached to this Note: X Exhibit A Modifications to Multifamily Note

  • Single Source Selection Services for tasks in circumstances which meet the requirements of paragraph 3.10 of the Consultant Guidelines for Single Source Selection, may, with the Association's prior agreement, be procured in accordance with the provisions of paragraphs 3.9 through 3.13 of the Consultant Guidelines.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!